<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Seastar Medical Holding Corporation — News on 6ix</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc</link>
<description>Latest news and press releases for Seastar Medical Holding Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 06 May 2026 12:20:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lmf-acquisition-opportunities-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683581b178dffbe2df0fbf47.webp</url>
<title>Seastar Medical Holding Corporation</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc</link>
</image>
<item>
<title>SeaStar Medical to Report First Quarter Financial Results on May 13, 2026</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-to-report-first-quarter-financial-results-on-may-13-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-to-report-first-quarter-financial-results-on-may-13-2026</guid>
<pubDate>Wed, 06 May 2026 12:20:00 GMT</pubDate>
<description>DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 13, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday, May 13, 2026, at 4:30 p</description>
</item>
<item>
<title>SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-showcases-new-positive-data-from-the-quelimmune-save-registry-and-an-analysis-of-the-unique-immunomodulatory-mechanism-of-the-scd-therapy-at-aki-and-crrt-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-showcases-new-positive-data-from-the-quelimmune-save-registry-and-an-analysis-of-the-unique-immunomodulatory-mechanism-of-the-scd-therapy-at-aki-and-crrt-2026</guid>
<pubDate>Mon, 30 Mar 2026 12:20:00 GMT</pubDate>
<description>Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data In vitro analysis of the SeaStar Medical SCD indicates modulation of the immune response, shifting monocytes towards an anti-inflammatory, reparative phenotype SeaStar Medical hosts an industry symposium and panel discussion focused on innovation in the treatment of pediatric AKI, supporting its emerging leadership in this community DENVER, March 30,</description>
</item>
<item>
<title>SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Wed, 25 Mar 2026 20:05:00 GMT</pubDate>
<description>Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage</description>
</item>
<item>
<title>SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-to-report-fourth-quarter-and-year-end-2025-financial-results-on-march-25-2026</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-to-report-fourth-quarter-and-year-end-2025-financial-results-on-march-25-2026</guid>
<pubDate>Wed, 18 Mar 2026 20:05:00 GMT</pubDate>
<description>DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2025 financial results after market close on Wednesday, March 25, 2026, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Wednesday,</description>
</item>
<item>
<title>SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-to-present-at-the-life-sciences-investor-forum-on-march-11th</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-to-present-at-the-life-sciences-investor-forum-on-march-11th</guid>
<pubDate>Mon, 09 Mar 2026 12:35:00 GMT</pubDate>
<description>The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com SeaStar Medical SeaStar Medical DENVER, March 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced</description>
</item>
<item>
<title>SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-completion-of-fda-enrollment-requirement-for-save-surveillance-registry-evaluating-quelimmune-safety-for-pediatric-aki-16</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-completion-of-fda-enrollment-requirement-for-save-surveillance-registry-evaluating-quelimmune-safety-for-pediatric-aki-16</guid>
<pubDate>Thu, 05 Mar 2026 13:20:00 GMT</pubDate>
<description>Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirementsDENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a Post-Approval Study (PAS) required by the FDA that is designed to confirm the safety of the QUELIMMUNE™ therapy as a treatment for children with acute kidney injury (AKI) due to sepsis o</description>
</item>
<item>
<title>ICU: Publication Validates Real-World Clinical Impact of QUELIMMUNE™ in Pediatric AKI</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/icu-publication-validates-real-world-clinical-impact-of-quelimmunetm-in-pediatric-aki</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/icu-publication-validates-real-world-clinical-impact-of-quelimmunetm-in-pediatric-aki</guid>
<pubDate>Wed, 11 Feb 2026 11:59:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:ICU READ THE FULL ICU RESEARCH REPORT Business Update Publication in Pediatric Nephrology Highlights Real-World QUELIMMUNE Data On February 9, 2026, SeaStar Medical Holding Corp. (NASDAQ:ICU) announced the publication of post-approval clinical experience for QUELIMMUNE™ (SCD-PED) in the peer-reviewed journal Pediatric Nephrology . The article, “Early post-approval</description>
</item>
<item>
<title>SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-publication-pediatric-132000731</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-publication-pediatric-132000731</guid>
<pubDate>Mon, 09 Feb 2026 13:20:00 GMT</pubDate>
<description>Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the publication of early post-approval clinical experience from the use of the QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the prestigious, p</description>
</item>
<item>
<title>SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-present-upcoming-noble-132500472</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-present-upcoming-noble-132500472</guid>
<pubDate>Thu, 29 Jan 2026 13:25:00 GMT</pubDate>
<description>DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, February 5th at 11:30 am Eastern Time. Interested investors and guests of SeaStar M</description>
</item>
<item>
<title>SeaStar Medical Announces 2026 Milestones</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-2026-milestones-131300353</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-2026-milestones-131300353</guid>
<pubDate>Wed, 07 Jan 2026 13:13:00 GMT</pubDate>
<description>Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical’s first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion market – through completion of enrollment of the NEUTRALIZE-AKI pivotal trial and initiation of the PMA process Progress the clinical development of the SCD therapy in patients with severe heart failure Leverage rapid pathways to commercialization of the SCD therapy through addition</description>
</item>
<item>
<title>SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-present-upcoming-biotech-135300951</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-present-upcoming-biotech-135300951</guid>
<pubDate>Tue, 06 Jan 2026 13:53:00 GMT</pubDate>
<description>DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at the Biotech Showcase 2026 Investor Conference at the Hilton Union Square, San Francisco, CA, on January 13, 2026, at 3:00 p.m. Pacific Standard Time. The live pr</description>
</item>
<item>
<title>SeaStar Medical Announces 1-for-10 Reverse Split</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-1-10-212500341</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-1-10-212500341</guid>
<pubDate>Tue, 23 Dec 2025 21:25:00 GMT</pubDate>
<description>DENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today the Company’s 1-for-10 reverse stock split (Reverse Split), which will become effective as of 12:01 a.m. Eastern Time on January 5, 2026. The Company’s common stock will begin trading on a post-split adjusted basis on The Nasdaq Capital Mark</description>
</item>
<item>
<title>SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-fda-approval-132700462</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-fda-approval-132700462</guid>
<pubDate>Tue, 02 Dec 2025 13:27:00 GMT</pubDate>
<description>FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients Compelling efficacy data to date along with completion of registry expected to expand QUELIMMUNE market opportunity DENVER, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the Center for Biologics Evaluation and Research (CBER) of the U.S. Food a</description>
</item>
<item>
<title>SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-present-upcoming-noblecon21-145200474</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-present-upcoming-noblecon21-145200474</guid>
<pubDate>Thu, 20 Nov 2025 14:52:00 GMT</pubDate>
<description>DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will present at NobleCon21 - Noble Capital Markets’ Twenty First Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Ra</description>
</item>
<item>
<title>SeaStar Medical Announces Appointment of Michael Messinger as CFO</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-appointment-michael-134300516</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-announces-appointment-michael-134300516</guid>
<pubDate>Mon, 17 Nov 2025 13:43:00 GMT</pubDate>
<description>DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a seasoned healthcare executive with over 25 years of industry experience, has joined SeaStar Medical as Chief Financial Officer. “Mike brings to SeaStar Medical a breadth of financial expertise, operational disciplin</description>
</item>
<item>
<title>SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-reports-third-quarter-210500765</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-reports-third-quarter-210500765</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>Business highlights include: Three new top-rated children’s hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Commercial use of QUELIMMUNE therapy demonstrates positive survival results as reported from the QUELIMMUNE SAVE Surveillance RegistryNew clinical sites added to expand adult NEUTRALIZE-AKI pivotal trial enrollmentStrengthened the balance sheet, raising $12.4 million to fund future operationsWebcast call today at 4:30 p.m. Eastern Time DENVER, Nov. 13,</description>
</item>
<item>
<title>SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-report-third-quarter-150300435</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-report-third-quarter-150300435</guid>
<pubDate>Wed, 05 Nov 2025 15:03:00 GMT</pubDate>
<description>DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Thursday, November 13, 2025, and host a webcast and conference call to discuss its financial results and business progress. Date/Time:Thursday, November 13, 2025,</description>
</item>
<item>
<title>SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-reports-positive-early-123600225</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-reports-positive-early-123600225</guid>
<pubDate>Mon, 29 Sep 2025 12:36:00 GMT</pubDate>
<description>Data show results consistent with clinical trial experienceA high level of safety – no device-related adverse eventsStrong survival data extending to 90 days DENVER, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveillance Registry presented on Saturday, September 27, 2025, at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Regis</description>
</item>
<item>
<title>SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-reports-dsmb-recommendation-202200778</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-reports-dsmb-recommendation-202200778</guid>
<pubDate>Wed, 24 Sep 2025 20:22:00 GMT</pubDate>
<description>Independent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the independent Data Safety Monitoring Review Board (DSMB) has recommended the</description>
</item>
<item>
<title>SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children</title>
<link>https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-present-early-save-122300722</link>
<guid isPermaLink="true">https://6ix.com/company/lmf-acquisition-opportunities-inc/news/seastar-medical-present-early-save-122300722</guid>
<pubDate>Tue, 23 Sep 2025 12:23:00 GMT</pubDate>
<description>DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE Surveillance Registry will be presented by SeaStar Medical and its research collaborators at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Registry presentation will highlight the role of QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the treatmen</description>
</item>
</channel>
</rss>